ECO Animal Health Group plc Stock

Equities

EAH

GB0032036807

Pharmaceuticals

Market Closed - London S.E. 11:35:18 2024-05-03 am EDT 5-day change 1st Jan Change
112.5 GBX 0.00% Intraday chart for ECO Animal Health Group plc +4.65% +3.69%
Sales 2024 * 89.31M 112M Sales 2025 * 92.82M 116M Capitalization 76.21M 95.61M
Net income 2024 * 2M 2.51M Net income 2025 * 2M 2.51M EV / Sales 2024 * 0.65 x
Net cash position 2024 * 18.58M 23.3M Net cash position 2025 * 17.61M 22.09M EV / Sales 2025 * 0.63 x
P/E ratio 2024 *
48.6 x
P/E ratio 2025 *
39.1 x
Employees 234
Yield 2024 *
-
Yield 2025 *
0.62%
Free-Float 83.05%
More Fundamentals * Assessed data
Dynamic Chart
1 week+4.65%
Current month+1.81%
1 month+32.35%
3 months+3.69%
6 months+4.65%
Current year+3.69%
More quotes
1 week
105.00
Extreme 105
114.50
1 month
84.50
Extreme 84.5
114.50
Current year
82.00
Extreme 82
114.50
1 year
82.00
Extreme 82
124.00
3 years
80.75
Extreme 80.75
405.00
5 years
80.75
Extreme 80.75
439.00
10 years
80.75
Extreme 80.75
685.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 22-03-31
Director of Finance/CFO 60 19-09-02
Chief Tech/Sci/R&D Officer - 13-12-31
Members of the board TitleAgeSince
Director/Board Member 67 20-04-30
Director of Finance/CFO 60 19-09-02
Director/Board Member 64 Feb. 11
More insiders
Date Price Change Volume
24-05-03 112.5 0.00% 25,212
24-05-02 112.5 +0.67% 19,070
24-05-01 111.8 +1.13% 20,176
24-04-30 110.5 +0.45% 86,866
24-04-29 110 +2.33% 67,946

Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT

More quotes
ECO Animal Health Group plc is a United Kingdom-based animal health biotechnology company. The Company is engaged in the manufacturing and supplying of animal health products globally. The Company is focused on providing solutions to respiratory and enteric diseases in pigs and poultry. It provides quality products for swine and poultry, primarily anti-infectives. The Company’s segment includes the United Kingdom, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World. The Company research, develops and commercializes products for livestock. The Company’s lead product, Aivlosin, is an antimicrobial which is used under veterinary prescription for the treatment of economically important respiratory and gastrointestinal diseases in pigs and poultry. The Company is also engaged in researching and developing new solutions to enhance the lives of pigs and poultry.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.125 GBP
Average target price
1.851 GBP
Spread / Average Target
+64.56%
Consensus

Annual profits - Rate of surprise